Claims for Patent: 8,906,896

Summary for Patent: 8,906,896

Title:	Platinum acridine anti-cancer compounds and methods thereof
Abstract:	Acridine containing cisplatin compounds are disclosed that show greater efficacy than other cisplatin compounds for treating cancer. The compounds are compounds of Formula I ##STR00001## wherein the variables are defined herein.
Inventor(s):	Bierbach; Ulrich (Winston-Salem, NC)
Assignee:
Application Number:	13/125,214
Patent Claims:	1. A compound of Formula I: ##STR00022## wherein X is halo, --OC(O)R.sub.9, nitrate or sulfate: R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sub.2 form the ring --NH.sub.2--(CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2 or 3, or R.sub.1 and R.sub.2 together can be any of the following groups a-h, or R.sub.1 and R.sub.2 independently can be any of the following groups i-m; ##STR00023## wherein A is H, --CH.sub.3, --OCH.sub.3, CF.sub.3, or NO.sub.2; R.sub.13 is independently C.sub.1-C.sub.6alkyl; R.sub.3 is --N(R.sub.6)--, wherein R.sub.6 is hydrogen or C.sub.1-C.sub.6alkyl; R.sub.4 is independently an amino, a nitro, --NHC(O)(R.sub.10), --C(O)NHR.sub.10, or halo; R.sub.1o is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norhornyl, or adamantyl; q is 0, 1, or 2; R.sub.5 is a direct bond, --NH-- or C.sub.1-C.sub.6alkylene; or R.sub.5 and X together with the atoms to which they are attached form a 6- or 7-membered ring, wherein said 6- or 7-membered ring contains a linking group --C(O)O-- or --OC(O)--; R.sub.7 is hydrogen, methyl, or --C(O)O--R.sub.8; wherein R.sub.8 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl, a natural or unnatural amino acid or a peptide; R.sub.9 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl; Y is C.sub.1-C.sub.6alkylene; and Z is one or more counterions sufficient to balance the charge of the compound. 2. The compound of claim 1, wherein R.sub.6 is hydrogen or methyl and R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sub.2 form the ring --NH.sub.2-- (CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2, or 3. 3. The compound of claim 2, wherein Y is --CH.sub.2--. 4. The compound of claim 3, wherein R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which R.sub.1 and R.sub.2 are attached are --NH.sub.2--CH.sub.2--NH.sub.2--. 5. The compound of claim 4, wherein the one or more counter ions of Z comprise NO.sub.3. 6. The compound of claim 5, wherein R.sub.5 is --NH-- or --CH.sub.2. 7. The compound of claim 6, wherein R.sub.6 is hydrogen. 8. The compound of claim 1, wherein the compound is Example 1 ##STR00024## 9. The compound of claim 1, wherein the compound is Example 2: ##STR00025## 10. A method of treating cancer comprising administering to a subject in need thereof an effective amount of the compound of Formula I: ##STR00026## wherein X is halo, --OC(O)R.sub.9, nitrate or sulfate; R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sub.2 form the ring --NH.sub.2--(CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2, or 3, or R.sub.1 and R.sub.2 together can be any of the following groups a-h or R.sub.1 and R.sub.2 independently can be any of the following groups i-m; ##STR00027## wherein A is H, --CH.sub.3, --OCH.sub.3, CF.sub.3 or NO.sub.2; R.sub.13 is independently C.sub.1-C.sub.6alkyl; R.sub.3 is --N(R.sub.6)--; wherein R.sub.6 is hydrogen or C.sub.1-C.sub.6alkyl; R.sub.4 is independently an amino, a nitro, --NHC(O)(R.sub.10), --C(O)NHR.sub.10, or halo; R.sub.10 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl; q is 0, 1, or 2; R.sub.5 is a direct bond, --NH-- or C.sub.1-C.sub.6alkylene; or R.sub.5 and X together with the atoms to which they are attached form a 6- or 7-membered ring, wherein said 6- or 7-membered ring contains a linking group --C(O)O-- or --OC(O)--; R.sub.7 is hydrogen, methyl, or --C(O)O--R.sub.8; wherein R.sub.8 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl, a natural or unnatural amino acid or a peptide; R.sub.9 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl; Y is C.sub.1-C.sub.6alkylene; and Z is one or more counterions sufficient to balance the charge of the compound. 11. The method of claim 10, wherein the cancer is selected from the group consisting of lung cancer, testicular cancers, ovarian carcinomas, head and neck cancers, leukemias and lymphomas. 12. The method of claim 11, wherein R.sub.6 is hydrogen or methyl and R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sub.2 form the ring --NH.sub.2-- (CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2, or 3. 13. The method of claim 12, wherein Y is --CH.sub.2--. 14. The method of claim 13, wherein R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which R.sub.1 and R.sub.2 are attached are --NH.sub.2--CH.sub.2--NH.sub.2--. 15. The method of claim 14, wherein the one or more counter ions of Z comprise NO.sub.3. 16. The method of claim 15, wherein R.sub.5 is --NH-- or --CH.sub.2--. 17. The method of claim 16, wherein R.sub.6 is hydrogen. 18. A pharmaceutical composition comprising the compound of Formula I: ##STR00028## wherein X is halo, --OC(O)R.sub.9, nitrate or sulfate; R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sup.2 form the ring --NH.sub.2--(CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2, or 3, or R.sub.1 and R.sub.2 together can be any of the following groups a-h or R.sub.1 and R.sub.2 independently can be any of the following groups i-m; ##STR00029## wherein A is H, --CH.sub.3, --OCH.sub.3, CF.sub.3 or NO.sub.2; R.sub.13 is independently C.sub.1-C.sub.6alkyl; R.sub.3 is --N(R.sub.6)--, wherein R.sub.6 is hydrogen or C.sub.1-C.sub.6alkyl; R.sub.4 is independently an amino, a nitro, --NHC(O)(R.sub.10), --C(O)NHR.sub.10, or halo; R.sub.10 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl; q is 0, 1, or 2; R.sub.5 is a direct bond, --NH-- or C.sub.1-C.sub.6alkylene; or R.sub.5 and X together with the atoms to which they are attached form a 6- or 7-membered ring, wherein said 6- or 7-membered ring contains a linking group --C(O)O-- or --OC(O)--; R.sub.7 is hydrogen, methyl, or --C(O)O--R.sub.8; wherein R.sub.8 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl, a natural or unnatural amino acid or a peptide; R.sub.9 is hydrogen, C.sub.1-6 alkyl, phenyl, naphthyl, C.sub.3-6 cycloalkyl, norbornyl, or adamantyl; Y is C.sub.1-C.sub.6alkylene; and Z is one or more counterions sufficient to balance the charge of the compound; and a pharmaceutically acceptable diluent, carrier, or excipient. 19. The pharmaceutical composition of claim 18, wherein Y is --CH.sub.2--, wherein R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which R.sub.1 and R.sub.2 are attached are --NH.sub.2--CH.sub.2-- NH.sub.2--, and wherein the one or more counter ions of Z comprise NO.sub.3. 20. The pharmaceutical composition of claim 19, wherein R.sub.5 is --NH-- or --CH.sub.2--, wherein R.sub.6 is hydrogen or methyl and R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sub.2 form the ring --NH.sub.2--(CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2, or 3. 21. The pharmaceutical composition of claim 18, further comprising one or more compounds selected from the group consisting of HERCEPTIN.TM. (trastuzumab), RITUXAN.TM. (rituximab), ZEVALIN.TM. (ibritumomab tiuxetan), LYMPHOCIDE.TM. (epratuzumab), GLEEVAC.TM., BEXXAR.TM. (iodine 131 tositumomab), ERBITUX.TM. (IMC-C225), KDR inhibitory agents, AVASTIN.TM., VEGF-TRAP.TM., ABX-EGF (panitumumab),IRESSA.TM. (gefitinib), TARCEVA.TM. (erlotinib), Campath, IL-8, B-FGF, Tek antagonists, anti-TWEAK agents, anti- PDGF-BB antagonists, SD-7784, cilengitide; pegaptanib octasodium; Alphastatin, M-PGA; ilomastat, emaxanib, vatalanib, 2-methoxyestradiol, TLC ELL- 12, anecortave acetate, alpha- D 148 Mab, CEP-7055, anti-Vn Mab, DAC:antiangiogenic, Angiocidin, KM-2550, SU-0879, CGP-79787, YIGSR-Stealth, fibrinogen-E fragment, TBC-1635; SC-236, ABT-567, Metastatin, maspin, ER-68203-00, Benefin, Tz-93, TAN-1120, FR-111142, platelet factor 4, vascular endothelial growth factor antagonist, bevacizumab (pINN), XL 784, XL 647, MAb, alpha5heat3 integrin, enzastaurin hydrochloride (USAN), CEP 7055, BC 1, VEGF antagonist, rBPI 21 and BPI-derived antiangiogenic, PI 88, cilengitide (pINN), cetuximab (INN), AVE 8062, AS 1404, SG 292, Endostatin, ATN 161, ANGIOSTATIN, ZD 6474, ZD 6126, PPI 2458, AZD 9935, AZD 2171, vatalanib (pINN), pegaptanib (Pinn), xanthorrhizol, SPV5.2, SDX 103, PX 478, METASTATIN, troponin I, SU 6668, OXI 4503, o-guanidines, motuporamine C, CDP 791, atiprimod (pINN), E 7820, CYC 381, AE 941, urokinase plasminogen activator inhibitor, oglufanide (pINN), HIF-lalfa inhibitors, CEP 5214, BAY RES 2622; Angiocidin, A6, KR 31372, GW 2286, EHT 0101, CP 868596, CP 564959, CP 547632, compound 786034 from GlaxoSmithKline, KRN 633, anginex ABT 510, AAL 993, VEGI, tumor necrosis factor-alpha inhibitors, SU 11248, ABT 518, YH 16, S-3APG, KDR, GFB 116, CS 706, combretastatin A4 prodrugs, chondroitinase AC, BAY RES 2690, AGM 1470, AG 13925, Tetrathiomolybdate, GCS 100, CV 247, CKD 732, irsogladine (INN), RG 13577, WX 360, squalamine (pIN), RPI 4610, heparanase inhibitors, KL 3106, Honokiol, ZK CDK, ZK Angio, ZK 229561, XMP 300, VGA 1102, Vasostatin, F1k-I, TZ 93, TumStatin, truncated soluble FLT 1 Tie-2 ligands and thrombospondin 1 inhibitor. 22. A method of making a compound of Formula X: ##STR00030## wherein X is a halo group; R.sub.1 and R.sub.2 are amino groups or together with the platinum atom to which they are attached, R.sub.1 and R.sub.7 form the ring --NH.sub.2--(CH.sub.2).sub.v--NH.sub.2-- wherein v is 1, 2, or 3, or R.sub.1 and R.sub.2 together can be any of the following groups a-h, or R.sub.1 and R.sub.2 independently can be an of the following groups i-m: ##STR00031## wherein A is H, --CH.sub.3, --OCH.sub.3, CF.sub.3 or NO.sub.2; R.sub.13 is independently C.sub.1-C.sub.6alkyl; R.sub.5 is a direct bond, --NH-- or C.sub.1-C.sub.6alkylene; and Z is one or more counterions sufficient to balance the charge of the compound comprising reacting a compound of Formula IV ##STR00032## with a compound of formula V ##STR00033## wherein all of the variables are defined as above. 23. The method of claim 10, wherein the cancer is non-small cell lung, leukemia, ovarian, pancreatic, breast, gastrointestinal, prostate, melanoma, acute leukemia, multiple myeloma, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, or lymphoid malignancies of T-cell or B-cell origin. 24. The method of claim 10, wherein the cancer is non-small cell lung, leukemia, ovarian, breast, or pancreatic. 25. The method of claim 10, wherein the cancer is non-small cell lung or leukemia.

Details for Patent 8,906,896

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2028-10-24
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-10-24
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-10-24
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-10-24